U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285889) titled 'First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)' on Dec. 03.
Brief Summary: This study aims to evaluate the optimal dose (Recommended Phase 2 Dose, RP2D), preliminary safety, and efficacy of gecacitinib (also known as jaktinib) in combination with glucocorticoids as first-line therapy for patients with grade II-IV acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Study Start Date: Dec. 03
Study Type: INTERVENTIONAL
Condition:
Acute Graft Versus Host Disease
Intervention:
DRUG: Gecacitinib (also known as Jaktinib) combined glucocorticoids
This clin...